Hepatitis C virus infection and injection drug users: Prevention, risk factors, and treatment

被引:71
作者
Backmund, M
Reimer, J
Meyer, K
Gerlach, JT
Zachoval, R
机构
[1] Gen Hosp Munich Schwabing, Dept Addict Med, D-80804 Munich, Germany
[2] Klinikum Grosshadern, Dept Med 2, Grosshadern, Germany
[3] Univ Hamburg, Ctr Interdisciplinary Addict Res, Hamburg, Germany
关键词
D O I
10.1086/427475
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Injection drug users (IDUs) are the largest group of persons infected with hepatitis C virus (HCV), with a prevalence of 50%-90%. The transmission of HCV is not the effect of the drug injected but of sharing contaminated equipment. For the sake of prevention, we have to know which factors are more likely to lead to HCV seroconversion and which particular situations and environments are risk factors for equipment sharing. As far as therapy is concerned, some studies have shown that treatment for HCV infection in IDUs during substitution treatment for drug dependency is as successful as is treatment of patients who are not IDUs. Screening and early treatment of IDUs could play an important role in controlling HCV infection. The rate of reinfection may not as high as supposed. All studies dealing with treatment for HCV infection in IDUs have stressed the necessity of collaboration among hepatologists and specialists in addiction medicine, social workers, and psychotherapists.
引用
收藏
页码:S330 / S335
页数:6
相关论文
共 60 条
  • [1] Epidemiology of hepatitis C
    Alter, MJ
    [J]. HEPATOLOGY, 1997, 26 (03) : S62 - S65
  • [2] Hepatitis C virus infection in the United States
    Alter, MJ
    [J]. JOURNAL OF HEPATOLOGY, 1999, 31 : 88 - 91
  • [3] RISK-FACTORS FOR ACUTE NON-A, NON-B HEPATITIS IN THE UNITED-STATES AND ASSOCIATION WITH HEPATITIS-C VIRUS-INFECTION
    ALTER, MJ
    HADLER, SC
    JUDSON, FN
    MARES, A
    ALEXANDER, WJ
    HU, PY
    MILLER, JK
    MOYER, LA
    FIELDS, HA
    BRADLEY, DW
    MARGOLIS, HS
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (17): : 2231 - 2235
  • [4] [Anonymous], 1999, J Hepatol, V30, P956
  • [5] Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy
    Asselah, T
    Vidaud, D
    Doloy, A
    Boyer, N
    Martinot, M
    Vidaud, M
    Valla, D
    Marcellin, P
    [J]. GUT, 2003, 52 (06) : 900 - 902
  • [6] Hepatitis C virus infection in injection drug users in Bavaria: Risk factors for seropositivity
    Markus Backmund
    Kirsten Meyer
    Martin Wächtler
    Dieter Eichenlaub
    [J]. European Journal of Epidemiology, 2003, 18 (6) : 563 - 568
  • [7] Treatment of hepatitis C infection in injection drug users
    Backmund, M
    Meyer, K
    Von Zielonka, M
    Eichenlaub, D
    [J]. HEPATOLOGY, 2001, 34 (01) : 188 - 193
  • [8] BACKMUND M, 2003, SUCHTMEDIZIN FORSCHU, V5, P258
  • [9] BACKMUND M, 2002, SUCHTTHERAPIE, V3, P67
  • [10] BACKMUND M, 2001, SUCHTMED, V3, P21